Shopping Cart 0
Cart Subtotal
AED 0

Dana-Farber Cancer Institute Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Dana-Farber Cancer Institute Inc (Dana-Farber), formerly Sidney Farber Cancer Center is a cancer research center that offers treatment for different types of cancers. The center offers adults and children with various treatment options and also focuses on diagnosis, treatment, cure, and prevention of cancer and related diseases. The institute has many ongoing clinical trials for cancer at Dana-Farber and its affiliated institutions. Dana-Farber also offers training to physicians and scientists and also promotes public health. The center collaborates with various hospitals and research institutions to offers its patients with advanced cancer care. Dana-Farber is headquartered in Boston, Massachusetts, the US.

Dana-Farber Cancer Institute Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Dana-Farber Cancer Institute Inc, Medical Devices Deals, 2012 to YTD 2018 10

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Lifespan Partners with Dana-Farber Cancer Institute 13

Cannabis Science Enters into Research Agreement with Dana Farber/Harvard Cancer Center 14

Daiichi Sankyo Enters into Research Agreement with Dana-Farber Cancer Institute 15

Genus Oncology Partners with Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center 16

Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 17

Dana-Farber Cancer Institute Enters into Research Agreement with Array BioPharma 18

Eli Lilly Expands Research Agreement with Dana-Farber Cancer Institute 19

Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 20

Dana-Farber Cancer Institute Enters into Research Agreement with Astellas Pharma 21

Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 22

GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount Sinai School of Medicine 23

Biocept Enters into Partnership with Dana-Farber Cancer Institute 25

Licensing Agreements 26

Novartis Enters into Licensing Agreement with SEAS, Wyss Institute for Biologically Inspired Engineering, Dana-Farber Cancer Institute and University of Michigan 26

C4 Therapeutics Enters into License Agreement with Dana-Farber Cancer Institute 28

Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute 29

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 31

Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 33

OncoPep Enters Into Licensing Agreement With Dana-Farber Cancer Institute For Cancer Vaccine Technology 34

Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 35

Dana-Farber Cancer Institute Inc-Key Competitors 36

Dana-Farber Cancer Institute Inc-Key Employees 37

Dana-Farber Cancer Institute Inc-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Government and Public Interest 40

Sep 06, 2018: Study finds immunotherapy may treat certain prostate cancers 40

Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 41

Jul 18, 2018: Study finds melanoma biomarkers predicting checkpoint blocker response 42

Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 43

Jun 26, 2018: Pancreatic Cancer Action Network Funds Innovative Scientists through Research Grants Program 44

Jun 21, 2018: Lustgarten Funded Study Shows Loss of Fat and Muscle is a Common First Sign of Pancreatic Cancer 45

Jun 04, 2018: First-Ever Scientific Research Awards Funded by ALK Positive in Partnership with LUNGevity Foundation 46

May 10, 2018: New Grants Totaling USD 2.6 Million Fund Work to Reduce Immunotherapy Side Effects 47

May 10, 2018: USD 5 million supports innovative breast cancer trial 48

Apr 03, 2018: Small genetic script causes drug resistance in some ovarian cancers 49

Mar 08, 2018: Three Dana-Farber researchers awarded new grant to accelerate multiple myeloma research 50

Mar 05, 2018: Personal cancer vaccines get their own boost 51

Feb 19, 2018: Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer 53

Jan 23, 2018: Damon Runyon Cancer Research Foundation awards USD 3M to eleven innovative early career scientists 55

Jan 02, 2018: Novel diabetes drugs sensitize cancer cells to chemotherapy agents 58

Dec 10, 2017: Low-dose treatment with interleukin-2 across multiple studies shows benefits in chronic graft-versus-host disease 59

Dec 09, 2017: Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant for hematologic cancers 61

Dec 08, 2017: Study shows young breast cancer survivors experience significant arm morbidity rates following surgery 62

Nov 02, 2017: Lung Cancer Research Foundation Awards USD 1.6 Million in Research Grants 63

Oct 17, 2017: Study finds potential prevention of common chemotherapy side effect 65

Oct 16, 2017: Gilead Awards USD 7.5 Million in Second Round of Grants to Advance HIV Cure Research 66

Oct 11, 2017: Discovery of peripheral neuropathy cause suggests potential preventive measures 67

Oct 06, 2017: FDA awards 15 grants for clinical trials to stimulate product development for rare diseases 68

Sep 19, 2017: CPRIT awards USD 34M to UTSW for cancer research recruitment 70

Jun 14, 2017: Harold Alfond Foundation Awards USD 10M to Launch MaineHealth Cancer Care Network 72

Mar 08, 2017: Novel compound that engages 'second arm' of immune system reduces breast tumors and metastases, study shows 74

Product News 75

Oct 23, 2017: A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children 75

Aug 22, 2018: Study of genomic changes in multiple myeloma may lead to new approaches to treating early, smoldering myeloma 76

Aug 06, 2018: Researchers claim to have uncovered how thalidomide caused birth defects 78

May 09, 2017: Combination treatment for advanced lung cancer does not improve survival 79

Mar 21, 2018: Gradual release of immunotherapy at site of tumor surgery prevents tumors from returning and eliminates cancer spread in mouse study 80

Other Significant Developments 82

Jun 14, 2018: Genetic Sequencing of Advanced Pancreatic Cancer Enables Personalized Medicine 82

Nov 20, 2017: LLS Funds USD 46 Million in New Research to Find Cures 83

Appendix 86

Methodology 86

About GlobalData 86

Contact Us 86

Disclaimer 86


List Of Figure

List of Figures

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Dana-Farber Cancer Institute Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Key Facts 2

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dana-Farber Cancer Institute Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Dana-Farber Cancer Institute Inc, Medical Devices Deals, 2012 to YTD 2018 10

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Lifespan Partners with Dana-Farber Cancer Institute 13

Cannabis Science Enters into Research Agreement with Dana Farber/Harvard Cancer Center 14

Daiichi Sankyo Enters into Research Agreement with Dana-Farber Cancer Institute 15

Genus Oncology Partners with Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center 16

Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 17

Dana-Farber Cancer Institute Enters into Research Agreement with Array BioPharma 18

Eli Lilly Expands Research Agreement with Dana-Farber Cancer Institute 19

Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 20

Dana-Farber Cancer Institute Enters into Research Agreement with Astellas Pharma 21

Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 22

GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount Sinai School of Medicine 23

Biocept Enters into Partnership with Dana-Farber Cancer Institute 25

Novartis Enters into Licensing Agreement with SEAS, Wyss Institute for Biologically Inspired Engineering, Dana-Farber Cancer Institute and University of Michigan 26

C4 Therapeutics Enters into License Agreement with Dana-Farber Cancer Institute 28

Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute 29

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 31

Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 33

OncoPep Enters Into Licensing Agreement With Dana-Farber Cancer Institute For Cancer Vaccine Technology 34

Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 35

Dana-Farber Cancer Institute Inc, Key Competitors 36

Dana-Farber Cancer Institute Inc, Key Employees 37

Dana-Farber Cancer Institute Inc, Other Locations 39

Dana-Farber Cancer Institute Inc, Subsidiaries 39

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Dana-Farber Cancer Institute Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Dana-Farber Cancer Institute Inc (Dana-Farber), formerly Sidney Farber Cancer Center is a cancer research center that offers treatment for different types of cancers. The center offers adults and children with various treatment options and also focuses on diagnosis, treatment, cure, and prevention of cancer and related diseases. The institute has many ongoing clinical trials for cancer at Dana-Farber and its affiliated institutions. Dana-Farber also offers training to physicians and scientists and also promotes public health. The center collaborates with various hospitals and research institutions to offers its patients with advanced cancer care. Dana-Farber is headquartered in Boston, Massachusetts, the US.

Dana-Farber Cancer Institute Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Dana-Farber Cancer Institute Inc, Medical Devices Deals, 2012 to YTD 2018 10

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Lifespan Partners with Dana-Farber Cancer Institute 13

Cannabis Science Enters into Research Agreement with Dana Farber/Harvard Cancer Center 14

Daiichi Sankyo Enters into Research Agreement with Dana-Farber Cancer Institute 15

Genus Oncology Partners with Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center 16

Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 17

Dana-Farber Cancer Institute Enters into Research Agreement with Array BioPharma 18

Eli Lilly Expands Research Agreement with Dana-Farber Cancer Institute 19

Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 20

Dana-Farber Cancer Institute Enters into Research Agreement with Astellas Pharma 21

Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 22

GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount Sinai School of Medicine 23

Biocept Enters into Partnership with Dana-Farber Cancer Institute 25

Licensing Agreements 26

Novartis Enters into Licensing Agreement with SEAS, Wyss Institute for Biologically Inspired Engineering, Dana-Farber Cancer Institute and University of Michigan 26

C4 Therapeutics Enters into License Agreement with Dana-Farber Cancer Institute 28

Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute 29

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 31

Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 33

OncoPep Enters Into Licensing Agreement With Dana-Farber Cancer Institute For Cancer Vaccine Technology 34

Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 35

Dana-Farber Cancer Institute Inc-Key Competitors 36

Dana-Farber Cancer Institute Inc-Key Employees 37

Dana-Farber Cancer Institute Inc-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Government and Public Interest 40

Sep 06, 2018: Study finds immunotherapy may treat certain prostate cancers 40

Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 41

Jul 18, 2018: Study finds melanoma biomarkers predicting checkpoint blocker response 42

Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 43

Jun 26, 2018: Pancreatic Cancer Action Network Funds Innovative Scientists through Research Grants Program 44

Jun 21, 2018: Lustgarten Funded Study Shows Loss of Fat and Muscle is a Common First Sign of Pancreatic Cancer 45

Jun 04, 2018: First-Ever Scientific Research Awards Funded by ALK Positive in Partnership with LUNGevity Foundation 46

May 10, 2018: New Grants Totaling USD 2.6 Million Fund Work to Reduce Immunotherapy Side Effects 47

May 10, 2018: USD 5 million supports innovative breast cancer trial 48

Apr 03, 2018: Small genetic script causes drug resistance in some ovarian cancers 49

Mar 08, 2018: Three Dana-Farber researchers awarded new grant to accelerate multiple myeloma research 50

Mar 05, 2018: Personal cancer vaccines get their own boost 51

Feb 19, 2018: Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer 53

Jan 23, 2018: Damon Runyon Cancer Research Foundation awards USD 3M to eleven innovative early career scientists 55

Jan 02, 2018: Novel diabetes drugs sensitize cancer cells to chemotherapy agents 58

Dec 10, 2017: Low-dose treatment with interleukin-2 across multiple studies shows benefits in chronic graft-versus-host disease 59

Dec 09, 2017: Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant for hematologic cancers 61

Dec 08, 2017: Study shows young breast cancer survivors experience significant arm morbidity rates following surgery 62

Nov 02, 2017: Lung Cancer Research Foundation Awards USD 1.6 Million in Research Grants 63

Oct 17, 2017: Study finds potential prevention of common chemotherapy side effect 65

Oct 16, 2017: Gilead Awards USD 7.5 Million in Second Round of Grants to Advance HIV Cure Research 66

Oct 11, 2017: Discovery of peripheral neuropathy cause suggests potential preventive measures 67

Oct 06, 2017: FDA awards 15 grants for clinical trials to stimulate product development for rare diseases 68

Sep 19, 2017: CPRIT awards USD 34M to UTSW for cancer research recruitment 70

Jun 14, 2017: Harold Alfond Foundation Awards USD 10M to Launch MaineHealth Cancer Care Network 72

Mar 08, 2017: Novel compound that engages 'second arm' of immune system reduces breast tumors and metastases, study shows 74

Product News 75

Oct 23, 2017: A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children 75

Aug 22, 2018: Study of genomic changes in multiple myeloma may lead to new approaches to treating early, smoldering myeloma 76

Aug 06, 2018: Researchers claim to have uncovered how thalidomide caused birth defects 78

May 09, 2017: Combination treatment for advanced lung cancer does not improve survival 79

Mar 21, 2018: Gradual release of immunotherapy at site of tumor surgery prevents tumors from returning and eliminates cancer spread in mouse study 80

Other Significant Developments 82

Jun 14, 2018: Genetic Sequencing of Advanced Pancreatic Cancer Enables Personalized Medicine 82

Nov 20, 2017: LLS Funds USD 46 Million in New Research to Find Cures 83

Appendix 86

Methodology 86

About GlobalData 86

Contact Us 86

Disclaimer 86


List Of Figure

List of Figures

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Dana-Farber Cancer Institute Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Key Facts 2

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Dana-Farber Cancer Institute Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Dana-Farber Cancer Institute Inc, Medical Devices Deals, 2012 to YTD 2018 10

Dana-Farber Cancer Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Lifespan Partners with Dana-Farber Cancer Institute 13

Cannabis Science Enters into Research Agreement with Dana Farber/Harvard Cancer Center 14

Daiichi Sankyo Enters into Research Agreement with Dana-Farber Cancer Institute 15

Genus Oncology Partners with Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center 16

Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 17

Dana-Farber Cancer Institute Enters into Research Agreement with Array BioPharma 18

Eli Lilly Expands Research Agreement with Dana-Farber Cancer Institute 19

Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 20

Dana-Farber Cancer Institute Enters into Research Agreement with Astellas Pharma 21

Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 22

GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount Sinai School of Medicine 23

Biocept Enters into Partnership with Dana-Farber Cancer Institute 25

Novartis Enters into Licensing Agreement with SEAS, Wyss Institute for Biologically Inspired Engineering, Dana-Farber Cancer Institute and University of Michigan 26

C4 Therapeutics Enters into License Agreement with Dana-Farber Cancer Institute 28

Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute 29

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 31

Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 33

OncoPep Enters Into Licensing Agreement With Dana-Farber Cancer Institute For Cancer Vaccine Technology 34

Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 35

Dana-Farber Cancer Institute Inc, Key Competitors 36

Dana-Farber Cancer Institute Inc, Key Employees 37

Dana-Farber Cancer Institute Inc, Other Locations 39

Dana-Farber Cancer Institute Inc, Subsidiaries 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Dana-Farber Cancer Institute Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.